tetano
Editor, Senior Moderator
Elife
. 2022 Nov 22;11:e79639.
doi: 10.7554/eLife.79639.
Exploratory data on the clinical efficacy of monoclonal antibodies against SARS-CoV-2 Omicron variant of concern
Fulvia Mazzaferri[SUP] 1 [/SUP], Massimo Mirandola[SUP] 1 [/SUP], Alessia Savoldi[SUP] 1 [/SUP], Pasquale De Nardo[SUP] 1 [/SUP], Matteo Morra[SUP] 1 [/SUP], Maela Tebon[SUP] 1 [/SUP], Maddalena Armellini[SUP] 1 [/SUP], Giulia De Luca[SUP] 1 [/SUP], Lucrezia Calandrino[SUP] 2 [/SUP], Lolita Sasset[SUP] 2 [/SUP], Denise D'Elia[SUP] 3 [/SUP], Emanuela Sozio[SUP] 3 [/SUP], Elisa Danese[SUP] 4 [/SUP], Davide Gibellini[SUP] 5 [/SUP], Isabella Monne[SUP] 6 [/SUP], Giovanna Scroccaro[SUP] 7 [/SUP], Nicola Magrini[SUP] 8 [/SUP], Annamaria Cattelan[SUP] 2 [/SUP], Carlo Tascini[SUP] 3 [/SUP], MANTICO Working Group; Evelina Tacconelli[SUP] 1 [/SUP]
Collaborators, Affiliations
Abstract
Background: Recent in-vitro data have shown that the activity of monoclonal antibodies (mAbs) targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) varies according to the variant of concern (VOC). No studies have compared the clinical efficacy of different mAbs against Omicron VOC.
Methods: The MANTICO trial is a non-inferiority randomised controlled trial comparing the clinical efficacy of early treatments with bamlanivimab/etesevimab, casirivimab/imdevimab, and sotrovimab in outpatients aged 50 or older with mild-to-moderate SARS-CoV-2 infection. As the patient enrolment was interrupted for possible futility after the onset of the Omicron wave, the analysis was performed according to the SARS-CoV-2 VOC. The primary outcome was coronavirus disease 2019 (COVID-19) progression (hospitalisation, need of supplemental oxygen therapy, or death through day 14). Secondary outcomes included the time to symptom resolution, assessed using the product-limit method. Kaplan-Meier estimator and Cox proportional hazard model were used to assess the association with predictors. Log rank test was used to compare survival functions.
Results: Overall, 319 patients were included. Among 141 patients infected with Delta, no COVID-19 progression was recorded, and the time to symptom resolution did not differ significantly between treatment groups (Log-rank Chi-square 0.22, p 0.90). Among 170 patients infected with Omicron (80.6% BA.1 and 19.4% BA.1.1), two COVID-19 progressions were recorded, both in the bamlanivimab/etesevimab group, and the median time to symptom resolution was 5 days shorter in the sotrovimab group compared with the bamlanivimab/etesevimab and casirivimab/imdevimab groups (HR 0.53 and HR 0.45, 95% CI 0.36-0.77 and 95% CI 0.30-0.67, p<0.01).
Conclusions: Our data suggest that, among adult outpatients with mild-to-moderate SARS-CoV-2 infection due to Omicron BA.1 and BA.1.1, early treatment with sotrovimab reduces the time to recovery compared with casirivimab/imdevimab and bamlanivimab/etesevimab. In the same population, early treatment with casirivimab/imdevimab may maintain a role in preventing COVID-19 progression. The generalisability of trial results is substantially limited by the early discontinuation of the trial and firm conclusions cannot be drawn.
Funding: This trial was funded by the Italian Medicines Agency (Agenzia Italiana del Farmaco, AIFA). The VOC identification was funded by the ORCHESTRA (Connecting European Cohorts to Increase Common and Effective Response to SARS-CoV-2 Pandemic) project, which has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement number 101016167.
Clinical trial number: NCT05205759.
Keywords: Omicron; bamlanivimab/etesevimab; casirivimab/imdevimab; early covid-19; human; medicine; monoclonal antibody; sotrovimab.
. 2022 Nov 22;11:e79639.
doi: 10.7554/eLife.79639.
Exploratory data on the clinical efficacy of monoclonal antibodies against SARS-CoV-2 Omicron variant of concern
Fulvia Mazzaferri[SUP] 1 [/SUP], Massimo Mirandola[SUP] 1 [/SUP], Alessia Savoldi[SUP] 1 [/SUP], Pasquale De Nardo[SUP] 1 [/SUP], Matteo Morra[SUP] 1 [/SUP], Maela Tebon[SUP] 1 [/SUP], Maddalena Armellini[SUP] 1 [/SUP], Giulia De Luca[SUP] 1 [/SUP], Lucrezia Calandrino[SUP] 2 [/SUP], Lolita Sasset[SUP] 2 [/SUP], Denise D'Elia[SUP] 3 [/SUP], Emanuela Sozio[SUP] 3 [/SUP], Elisa Danese[SUP] 4 [/SUP], Davide Gibellini[SUP] 5 [/SUP], Isabella Monne[SUP] 6 [/SUP], Giovanna Scroccaro[SUP] 7 [/SUP], Nicola Magrini[SUP] 8 [/SUP], Annamaria Cattelan[SUP] 2 [/SUP], Carlo Tascini[SUP] 3 [/SUP], MANTICO Working Group; Evelina Tacconelli[SUP] 1 [/SUP]
Collaborators, Affiliations
- PMID: 36413383
- DOI: 10.7554/eLife.79639
Abstract
Background: Recent in-vitro data have shown that the activity of monoclonal antibodies (mAbs) targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) varies according to the variant of concern (VOC). No studies have compared the clinical efficacy of different mAbs against Omicron VOC.
Methods: The MANTICO trial is a non-inferiority randomised controlled trial comparing the clinical efficacy of early treatments with bamlanivimab/etesevimab, casirivimab/imdevimab, and sotrovimab in outpatients aged 50 or older with mild-to-moderate SARS-CoV-2 infection. As the patient enrolment was interrupted for possible futility after the onset of the Omicron wave, the analysis was performed according to the SARS-CoV-2 VOC. The primary outcome was coronavirus disease 2019 (COVID-19) progression (hospitalisation, need of supplemental oxygen therapy, or death through day 14). Secondary outcomes included the time to symptom resolution, assessed using the product-limit method. Kaplan-Meier estimator and Cox proportional hazard model were used to assess the association with predictors. Log rank test was used to compare survival functions.
Results: Overall, 319 patients were included. Among 141 patients infected with Delta, no COVID-19 progression was recorded, and the time to symptom resolution did not differ significantly between treatment groups (Log-rank Chi-square 0.22, p 0.90). Among 170 patients infected with Omicron (80.6% BA.1 and 19.4% BA.1.1), two COVID-19 progressions were recorded, both in the bamlanivimab/etesevimab group, and the median time to symptom resolution was 5 days shorter in the sotrovimab group compared with the bamlanivimab/etesevimab and casirivimab/imdevimab groups (HR 0.53 and HR 0.45, 95% CI 0.36-0.77 and 95% CI 0.30-0.67, p<0.01).
Conclusions: Our data suggest that, among adult outpatients with mild-to-moderate SARS-CoV-2 infection due to Omicron BA.1 and BA.1.1, early treatment with sotrovimab reduces the time to recovery compared with casirivimab/imdevimab and bamlanivimab/etesevimab. In the same population, early treatment with casirivimab/imdevimab may maintain a role in preventing COVID-19 progression. The generalisability of trial results is substantially limited by the early discontinuation of the trial and firm conclusions cannot be drawn.
Funding: This trial was funded by the Italian Medicines Agency (Agenzia Italiana del Farmaco, AIFA). The VOC identification was funded by the ORCHESTRA (Connecting European Cohorts to Increase Common and Effective Response to SARS-CoV-2 Pandemic) project, which has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement number 101016167.
Clinical trial number: NCT05205759.
Keywords: Omicron; bamlanivimab/etesevimab; casirivimab/imdevimab; early covid-19; human; medicine; monoclonal antibody; sotrovimab.